Pfizer Inc. (0Q1N.L)
| Previous close | 50.58 |
| Open | 50.82 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 50.26 - 50.82 |
| 52-week range | 50.26 - 50.82 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 06 Feb 2023 - 10 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.30 |
- Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK, November 28, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business; Kevin Sullivan, Global Specialty Care & U.S. President; and Navin Katyal, U.S. Commercial and Global Business Lead for mRNA Portfolio, at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 4:20 p.m. EST.
- GlobeNewswire
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant tumors support the initiation of two Phase 3 registrational trials NEW HAVEN, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced initial results from the Phase 2 cohort expansion portion (VERITAC) of a phase 1/2 study with ARV-471,
- Yahoo Finance
Vaccinating the unvaxxed is key to end pandemic: Former FDA official
Hundreds of Americans die each day from COVID — and the unvaccinated make up a majority of those dead and hospitalized.
